Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


In the media

Cost of cancer drugs

Elizabeth Sukkar, deputy news editor of The Pharmaceutical Journal, talked to BBC Radio Leicester about the cost of cancer drugs and cost of developing new medicines.

She discussed the recent announcement made by NHS England that 25 clinical indications of life-extending cancer drugs will no longer be available to patients in England through the cancer drugs fund (CDF).

Sukkar said: “The CDF is raising very legitimate concerns on how the NHS values different treatments. The rationing of medicines is not unique to the UK. It is happening around the world.”

She explained that despite the R&D intensity, innovation success rates have declined compared to previous decades. The increase in R&D costs is driven by two factors, she said. Straightforward diseases have been tackled, so there is an increasing focus on complex pathologies, such as research into anti-cancer drugs; and is also driven by the stricter regulatory burden, which makes clinical testing expensive.

“The bulk of the R&D costs are in clinical trials, making up over 43% of total R&D costs,” she said.

Listen to the BBC Radio Leicester interview here.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20067623

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Essentials of Economic Evaluation in Healthcare

    Essentials of Economic Evaluation in Healthcare

    An introduction to economic evaluation specific to healthcare, for those with little or no knowledge of economics. Covers cost effectiveness, cost utility and cost benefit analysis.

    £33.00Buy now
  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons is the definitive reference source of analytical data for drugs and poisons.

    £535.00Buy now
PJJ Static MPU
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.